Omega-3-carboxylic Acids Patent Expiration
Omega-3-Carboxylic Acids is Used for lowering high levels of triglycerides in adult patients. It was first introduced by Astrazeneca Pharmaceuticals Lp
Omega-3-carboxylic Acids Patents
Given below is the list of patents protecting Omega-3-carboxylic Acids, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Epanova | US10117844 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | Jan 04, 2033 | Astrazeneca |
| Epanova | US5792795 | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
May 13, 2020
(Expired) | Astrazeneca |
| Epanova | US5948818 | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
May 13, 2020
(Expired) | Astrazeneca |
| Epanova | US7960370 | Type A gelatin capsule containing PUFA in free acid form | Dec 20, 2026 | Astrazeneca |
| Epanova | US8383678 | Type a gelatin capsule containing PUFA in free acid form | Feb 07, 2025 | Astrazeneca |
| Epanova | US9012501 | Type A gelatin capsule containing PUFA in free acid form | Feb 07, 2025 | Astrazeneca |
| Epanova | US9050308 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | Jan 04, 2033 | Astrazeneca |
| Epanova | US9050309 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | Jan 04, 2033 | Astrazeneca |
| Epanova | US9132112 | Type A gelatin capsule containing PUFA in free acid form | Feb 07, 2025 | Astrazeneca |